# Endo Epa Ethyl Ester T2d Statin Residual Tg

> Adding EPA ethyl ester for type 2 diabetes on statin with residual hypertriglyceridemia

- Skill: `dromlakhani/endo-epa-ethyl-ester-t2d-statin-residual-tg` (Agent Skill)
- Install (CLI): `npx skillmds@latest add dromlakhani/endo-epa-ethyl-ester-t2d-statin-residual-tg`
- Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/endo-epa-ethyl-ester-t2d-statin-residual-tg/raw
- Safety review: pending (external: skill-scanner PASS, skillspector PASS)
- Works with: Claude Code, Claude.ai, OpenAI Codex
- Category: Coding & Dev Tools
- Author: dromlakhani (https://skillmd.com/u/dromlakhani)
- Updated: 2026-09-21
- Page: https://skillmd.com/skills/dromlakhani/endo-epa-ethyl-ester-t2d-statin-residual-tg

---


# Adding EPA ethyl ester for type 2 diabetes on statin with residual hypertriglyceridemia

## STEP 1 — Gather Information
Collect: type 2 diabetes diagnosis, current statin therapy, LDL-C level (confirm at goal <70 mg/dL), triglyceride level, and presence of two additional traditional risk factors (e.g., hypertension, low HDL-C <40 mg/dL men/<50 mg/dL women, smoking, family history of premature ASCVD) or risk-enhancing factors (elevated Lp(a) ≥50 mg/dL, hsCRP >3 mg/L, CKD, microalbuminuria, retinopathy, etc.). Also assess ASCVD risk if needed for context.

## STEP 2 — Rule In / Rule Out
Is the patient on a statin with LDL-C at goal (<70 mg/dL) and triglyceride level >150 mg/dL? If YES, proceed to Step 3; if NO, do not add EPA ethyl ester and consider other TG-lowering strategies.

## STEP 3 — Classify or Stratify
Does the patient have at least two additional traditional risk factors or risk-enhancing factors? If YES, classify as candidate for EPA ethyl ester; if NO, do not add EPA ethyl ester and manage per standard lipid guidelines.

## STEP 4 — Decide
Add eicosapentaenoic acid ethyl ester 4 g/day to reduce cardiovascular risk; re-evaluate lipids and tolerability in 4–12 weeks.

## Clinical Guardrails / Mimics / Pitfalls
Do not use if triglycerides ≥500 mg/dL (consider fibrate instead); avoid in pregnancy or active liver disease; monitor for atrial fibrillation and bleeding; EPA ethyl ester does not significantly lower LDL-C, so LDL goal must already be met with statin; if EPA ethyl ester unavailable, consider fenofibrate as alternative.

## Clinical Example
A 58‑year‑old man with type 2 diabetes on atorvastatin 20 mg daily has LDL‑C 65 mg/dL, triglycerides 180 mg/dL, hypertension, and HDL‑C 38 mg/dL. He meets criteria: statin at LDL goal, TG >150 mg/dL, plus two risk factors (hypertension, low HDL). Prescribe EPA ethyl ester 4 g/day.

**Source:** Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2020, https://doi.org/10.1210/clinem/dgaa674
> **TODO:** consider adding scripts/calc.py for the endo-epa-ethyl-ester-t2d-statin-residual-tg calculator